Evidence map›Paper›PMID 12379876›Full record

ReviewOncogene2002

Epidemiology of tobacco use in the United States.

Gary A Giovino

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01542437 (Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2), which is not on this map. Cited by 96 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01542437 phase2completednot on this mapstarted 2012, after this paper: background citation

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2

TypeinterventionalSponsorInstituto Nacional de Cancerologia de MexicoRan2012 to 2017Enrolled66ConditionsNon-Small Cell Lung Cancer, EGFR, HER-2ArmsBIBW 2992
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 1 synthesis or guideline pooled it, 311 citations in OpenAlex.

  1. The feasibility of smoking reduction: an update.Addiction (Abingdon, England) · 2005
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Epidemiology of the U.S. opioid crisis: the importance of the vector.Annals of the New York Academy of Sciences · 2019
    Article
  20. An Exome-Wide Association Study Identifies New Susceptibility Loci for Age of Smoking Initiation in African- and European-American Populations.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gary A GiovinoDepartment of Cancer Prevention, Epidemiology, and Biostatistics, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, New York, NY 14263, USA. Gary.Giovino@RoswellPark.org
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christine B. Ambrosone · 1985 to 2026
$116.6M
NCI NIH HHS P30 CA16056-26
6 · The paper itself

Abstract

Efforts to understand trends in and patterns of lung cancer are well served by studies of trends in and patterns of tobacco use. In the United States, the manufactured cigarette emerged as the tobacco product of choice shortly after the turn of the twentieth century. Lung cancer emerged after years of inhalation of cigarette smoke, first among men and then among women. The massive public health education campaign that began after scientists recognized the dangers of cigarette smoking has contributed to large reductions in cigarette use and subsequent smoking-attributable morbidity and mortality. Since 1965, the prevalence of cigarette smoking among US adults has declined by almost half, with positive trends observed among persons in almost all sociodemographic groups and efforts to reduce disparities recognized as an important goal in public health. An epidemiologic approach to understanding and controlling patterns of tobacco use is proposed. The model focuses on the agent (tobacco products), host (consumer or potential consumer), vector (tobacco companies and other users), and environment (with influences from families, social sources, culture, history, politics, law, and media). Accelerating progress in reducing tobacco use will accelerate reductions in tobacco-attributable morbidity and mortality.

Indexed as

AdolescentAdultAge FactorsEducational StatusHumansPrevalenceSmokingUnited States

Identifiers

PMID12379876
OpenAlexW2010836341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.